StockUS listing USBBOTNASDAQHealthcareCapital Destroyer

BridgeBio Oncology Therapeutics, Inc.(BBOT) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk43Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 145.25M
Reward Ratingⓘ39 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ43 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BBOT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BridgeBio Oncology Therapeutics, Inc.?

, a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.

AI Brief Pro

The brief on BridgeBio Oncology Therapeutics, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is BridgeBio Oncology Therapeutics, Inc.?

, a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 145.25M, and a P/E ratio of 3.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (39)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap145.25M
P/E Ratio3.4151
Beta0.855
Insider Activity
12M windowNo data
No insider activity data available for this ticker.